Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms

Journal of Clinical Psychopharmacology
Karin HedenmalmOlav Spigset

Abstract

Extrapyramidal symptoms (EPS) are rare adverse drug reactions to selective serotonin reuptake inhibitors (SSRIs). This study aimed to investigate the potential risk factors for EPS associated with SSRIs including polymorphisms of cytochrome P-450 isoenzymes, and serotonin and dopamine transporters and receptors. All spontaneous adverse drug reaction reports received by the Swedish Medical Products Agency until December 1999 that were coded with EPS and judged to be at least possibly related to SSRI treatment were included in the study. Reporting physicians received a form for collection of relevant information including current and previous use of SSRIs and antipsychotics, alcohol or substance abuse, central nervous system damage, a history of epilepsy or EPS, and a family history of Parkinson disease. A blood sample was also requested for genotyping of selected cytochrome P-450, and serotonin and dopamine transporter and receptor mutations. A total of 64 cases of EPS were reported. Twenty-eight forms (46%) were returned, and 20 blood samples were obtained. Identified potential risk factors included age of 65 years or older and the presence of the A1 allele of the D2 dopamine receptor gene (DRD2) Taq1A polymorphism (relative ri...Continue Reading

References

Jan 1, 1995·The American Journal of Psychiatry·D M Coulter, P I Pillans
Dec 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·D K Arya
May 1, 1993·Acta Psychiatrica Scandinavica·E JönssonG Sedvall
Oct 1, 1996·The Journal of Clinical Psychiatry·R J Leo
Jan 7, 1998·The Annals of Pharmacotherapy·C F Caley
Aug 14, 1998·Molecular Psychiatry·M O KrebsM F Poirier
Jan 28, 1999·Biochemical and Biophysical Research Communications·U YasarF Sjöqvist
Jan 14, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·R L OliveriA Quattrone
Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·L GrevleJ Aasly
Feb 20, 2002·British Journal of Clinical Pharmacology·Leif BertilssonAyman Al-Shurbaji
Jun 14, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bernard LererFabio Macciardi
Dec 24, 2002·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Ernest P Noble
Mar 26, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Sîan M J HemmingsDan J Stein
Sep 30, 2003·The American Journal of Psychiatry·Greer M MurphyAlan F Schatzberg
Oct 21, 2003·Nature Neuroscience·Dominique J-F de QuervainAndreas Papassotiropoulos
Oct 24, 2003·Biological Psychiatry·Roy H PerlisMaurizio Fava
Jan 22, 2004·European Journal of Human Genetics : EJHG·Julien MendlewiczChristine Van Broeckhoven
Aug 25, 2004·The Journal of Clinical Psychiatry·Cristian DamsaStefan Beyenburg
Sep 24, 2004·Current Topics in Medicinal Chemistry·Cüneyt Güzey, Olav Spigset

❮ Previous
Next ❯

Citations

Jan 2, 2008·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Harish RamakrishnaJuraj Sprung
Jan 26, 2008·International Journal of Technology Assessment in Health Care·Louise HerbildMickael Bech
Sep 18, 2008·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Steven P CercyThomas Wisniewski
Nov 4, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Emanuela MorelliMark S Ansorge
Oct 17, 2013·Indian Journal of Pharmacology·Sai Krishna TikkaBasudeb Das
Mar 3, 2012·Pharmacogenomics·Sneha Narasimhan, Falk W Lohoff
Jul 19, 2013·Pharmacogenomics·Rosario López-RodríguezFrancisco Abad-Santos
Jun 27, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Norio Yasui-FurukoriSunao Kaneko
Jun 30, 2009·Pharmacotherapy·Kelan L H Thomas, Vicki L Ellingrod
Feb 7, 2007·Acta Psychiatrica Scandinavica. Supplementum·G S Malhi, M Berk
Jun 3, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Abdesslem KhiatYvan Boulanger
Apr 6, 2013·Human Psychopharmacology·Teresa CabaleiroFrancisco Abad-Santos
Apr 4, 2007·The American Journal of Medicine·David B GoldsteinSanjay M Sisodiya
Nov 6, 2007·The International Journal of Neuropsychopharmacology·Aysegul Yolga Tahiroglu, Ayse Avci
Aug 16, 2016·The Psychiatric Clinics of North America·Joseph F Goldberg, Carrie L Ernst
Dec 9, 2008·Clinics in Laboratory Medicine·Bronwyn Ramey-HartungKristen K Reynolds
Jul 7, 2009·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Leonardo Caixeta
Jul 19, 2008·Journal of Psychopharmacology·C MoretM Briley
Dec 17, 2008·Journal of Psychopharmacology·S H Kennedy
Jul 29, 2009·Harvard Review of Psychiatry·Zeina ChemaliGregory Fricchione
May 16, 2008·Journal of Clinical Psychopharmacology·Enrique López-TorresAdrián Llerena
Sep 16, 2010·Journal of Clinical Psychopharmacology·Panagiotis FerentinosLefteris Lykouras
Jul 28, 2019·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Sabrina MörklSiegfried Kasper
Oct 30, 2013·Neurologia i neurochirurgia polska·T LitwinA Członkowska
Mar 16, 2021·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Dania Abu-NaserRenad Abunaser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here